Summary
Conclusion
Celiac artery infusion (CAI) seems to be a qualified and successful method for adjuvant treatment of pancreatic cancer. To improve the dismal prognosis of resected pancreatic cancer patients, we performed postoperative regional chemotherapy via the celiac axis.
Background
From 1994–1995, 20 patients with pancreatic cancer (18 ductal adenocarcinoma, 2 cystadenocarcinoma) received adjuvant celiac axis intra-arterial infusions (CAI) after resection of their tumors. Sixteen patients had macroscopically complete tumor removal (R0/R1 resection, 80% of the patients), whereas four patients had gross residual disease remaining after resection (R2 resection, 20% of the patients). Postoperative tumor stages were UICC I in 1 patient, UICC II in 3 patients, and UICC III in 16 patients.
Methods
CAI was performed for six postoperative cycles via catheters placed into the celiac artery using Seldinger's technique. The chemotherapeutic protocol consisted of mitoxantrone (Novantron®), Wyeth-Lederle (Münster, Germany) 10 mg/m2 (d 1), folinic acid (Leucovorin®, Wyeth-Lederle, or Rescuvolin®, Medac, Hamburg, Germany) 170 mg/m2 for 10 min, followed, by 5-FU (Fluoroblastin®, Farmitalia, Freiburg, Germany), 600 mg/m2 for 120 min (d 2–4), and Cisplatin (Cisplatin-medac®, Medac) 60 mg/m2 (d5). The cycles were repeated after a rest period of 4 wk. Cisplatin infusions were accompanied by supportive antiemetic (8 mg Tropisetrone iv [Navoban®, Sandoz, Nürnberg, Germany] and 8 mg Dexametason iv) and diuretic measures.
Results
Toxicity WHO III occurred in 8%, of 100 cycles, and no toxic side effects WHO IV were encountered. The median survival of 21 mo in the treated group was nearly twice as long as the 9.3 mo of a historical matched control group (p<0.0003) CAI seems to be a qualified and successful method for adjuvant treatment of pancreatic cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gudjonsson B. Cancer of the pancreas: 50 years of surgery.Cancer 1987; 60: 2284–2303.
Gall FP, Zirngibl, H. Maligne tumoren des pankreas und der periampullären region, inChirurgische Onkologie-Histologie-und stadiengerechte Therapie maligner Tumoren, Gall FP, Hermanek P, Tonak J, eds. Springer-Verlag, Berlin, Heidelberg, New York, 1986; 416–460.
Warshaw AL, Fernández-Del Castillo C. Pancreatic carcinoma.N Engl J Med 1992; 326: 455–465.
Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer.Cancer 1987; 59: 2006–2010.
Gastrointestinal Tumor Study Group. Treatment of locally resectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone.J Natl Cancer Inst 1988; 80: 751–755.
Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation & chemotherapy following curative resection.Arch Surg 1994; 120: 899–903.
Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater results of a controlled, prospective randomised multicentre study.Eur J Cancer 1993; 29A: 698–703.
Link K, Staib L, Kreuser ED, Beger HG. Adjuvant treatment of colon and rectal cancer: impact of chemotherapy, radiotherapy, and immunotherapy on routine postsurgical patient management.Rec Res Cancer Res 1996; 142: 321.
Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery.Br J Surg 1994; 81: 102–107.
Link KH, Gansauge F, Pillasch J, Rilinger N, Büchler M, Beger HG. Regional treatment of advanced nonresectable and of resected pancreatic cancer via celiac axis infusion. First results of a single institution study.Dig Surg 1994; 11: 414–419.
Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG. Regionale chemotherapie beim fortgeschrittenen Pankreaskarzinom.Med Klin 1995; 90: 501–505.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment.Cancer 1981; 47: 207–214.
Arbuck SG. Overview of chemotherapy for pancreatic cancer.Int J Pancreatol 1990; 7: 209–222.
Douglass HO Jr. Adjuvant therapy for pancreatic cancer.World J Surg 1995; 19: 270–274.
Foo ML, Gunderson LL, Nagorney DM, McLlrath DC, Heerden van JA, Robinow JS, Kvols LK, Garton GR, Martenson JA, Cha SS. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ±5 fluorouracil.Int J Radiat Oncol Biol Phys 1993; 26: 483–489.
Whittington R, Solin L, Mohiuddin ME. Multimodality therapy of localized unresectable pancreatic adenocarcinoma.Cancer 1984; 54: 1991–1998.
Beger HG, Büchler MW, Friess H. Chirurgische Ergebnisse und Indikation zu adjuvanten Massnahmen beim Pankreascarcinom.Chirurg 1994; 65: 246–252.
Russell R. Surgical resection for cancer of the pancreas.Clin Gastroenterol 1990; 4: 889–916.
Casper ES. Pancreatic cancer: how can we progress?Eur J Cancer 1993; 29A: 171,172.
Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, Nakamori S, Hiratsuka M, Imaoka S. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.Am J Surg 1994; 168: 361–364.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Link, KH., Gansauge, F., Rilinger, N. et al. Celiac artery adjuvant chemotherapy. Int J Pancreatol 21, 65–69 (1997). https://doi.org/10.1007/BF02785922
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02785922